Skip to content
Research Article Open access CC BY 4.0

Use of Enoxaparin in Obstetrics and Gynecology Department

Nehad J. Ahmed

Journal of Pharmaceutical Research International · pp. 1–5 · Published 25 May 2020

10.9734/jpri/2020/v32i830464

Abstract

Aims: This study aims to demonstrate the use of enoxaparin in obstetrics and gynecology department in Alkharj. Methodology: This is a retrospective study was conducted in a public hospital in Alkharj city. The outpatient prescriptions were reviewed to evaluate the prescription patterns of enoxaparin. The data were collected and analyzed using Excel software, the descriptive data were represented by frequencies and percentages. Results: About 86.32% of the prescriptions contain enoxaparin syringe were prescribed for female patients. The majority of enoxaparin prescriptions were from obstetrics & gynecology department (79.48%).Moreover, the majority of enoxaparin prescriptions were prescribed by consultants (62.39%). Conclusion: The result of this study show that enoxaparin was prescribed commonly in the obstetrics and gynecology department for female patients because of its efficacy and safety profile. Enoxaparin is safer than other anticoagulants but still could cause many adverse effects so it is important to increase the health care professional awareness about its use.

Use enoxaparin obstetrics gynecology pregnancy

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.